Ana Victoria Marco Hernández

Dr. Ana Victoria Marco Hernández

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
SMSonia Mayo
Sonia Mayo
IGIrene Gómez-Manjón
Irene Gómez-Manjón
AHAna Victoria Marco Hernández
Ana Victoria Marco Hernández
JMJavier Fernández Martínez
Javier Fernández Martínez
ACAna Camacho
Ana Camacho
FMFrancisco Martinez
Francisco Martinez
N-type voltage-gated calcium channel controls the release of neurotransmitters from neurons. The association of other voltage-gated calcium channels with epilepsy is well-known. The association of N-type voltage-gated calcium channels and pain has also been established. However, the relationship between this type of calcium channel and epilepsy has not been specifically reviewed. Therefore, the present review systematically summarizes existing publications regarding the genetic associations between N-type voltage-dependent calcium channel and epilepsy.

29 November 2021 in Clinical Genetics
Verified
Journal Article
Closed access
PDF file
AHAna Victoria Marco Hernández
Ana Victoria Marco Hernández
MTMiguel Tomás‐Vila
Miguel Tomás‐Vila
AMAlejandro Montoya‐Filardi
Alejandro Montoya‐Filardi
HBHonorio Barranco‐González
Honorio Barranco‐González
JPJuan Jesus Vilchez Padilla
Juan Jesus Vilchez Padilla
FMFrancisco Martínez‐Castellano
Francisco Martínez‐Castellano

30 September 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
AHAna Victoria Marco Hernández
Ana Victoria Marco Hernández
ACAlfonso Caro
Alfonso Caro
AFAlejandro Montoya Filardi
Alejandro Montoya Filardi
MVMiguel Tomás Vila
Miguel Tomás Vila
SMSandra Monfort
Sandra Monfort
FMFrancisco Martinez
Francisco Martinez

8 July 2024 in Journal of Inherited Metabolic Disease
Verified
Journal Article
Open access
MFMaría Alcázar Fabra
María Alcázar Fabra
APAbraham J. Paredes-Fuentes
Abraham J. Paredes-Fuentes
MCManuel Torralba Carnerero
Manuel Torralba Carnerero
DFDaniel José Moreno Fernández-Ayala
Daniel José Moreno Fernández-Ayala
ALAntonio Arroyo Luque
Antonio Arroyo Luque
Carlos Santos-OcañaCarlos Santos-Ocaña
Carlos Santos-Ocaña
The protein encoded by COQ7 is required for CoQ10 synthesis in humans, hydroxylating 3‐demethoxyubiquinol (DMQ10) in the second to last steps of the pathway. COQ7 mutations lead to a primary CoQ10 deficiency syndrome associated with a pleiotropic neurological disorder. This study shows the clinical, physiological, and molecular characterization of four new cases of CoQ10 primary deficiency caused by five mutations in COQ7, three of which have not yet been described, inducing mitochondrial dysfunction in all patients. However, the specific combination of the identified variants in each patient generated precise pathophysiological and molecular alterations in fibroblasts, which would explain the differential in vitro response to supplementation therapy. Our results suggest that COQ7 dysfunction could be caused by specific structural changes that affect the interaction with COQ9 required for the DMQ10 presentation to COQ7, the substrate access to the active site, and the maintenance of the active site structure. Remarkably, patients' fibroblasts share transcriptional remodeling, supporting a modification of energy metabolism towards glycolysis, which could be an adaptive mechanism against CoQ10 deficiency. However, transcriptional analysis of mitochondria‐associated pathways showed distinct and dramatic differences between patient fibroblasts, which correlated with the extent of pathophysiological and neurological alterations observed in the probands. Overall, this study suggests that the combination of precise genetic diagnostics and the availability of new structural models of human proteins could help explain the origin of phenotypic pleiotropy observed in some genetic diseases and the different responses to available therapies.

Verified
Journal Article
Open access
PDF file
LMLola Martínez
Lola Martínez
IHIsabel Hinarejos
Isabel Hinarejos
HAHerminia Argente-Escrig
Herminia Argente-Escrig
CMClara Marco Marín
Clara Marco Marín
MAMaría Ana Lozano Aroca
María Ana Lozano Aroca
Carmen EspinósCarmen Espinós
Carmen Espinós
Cerebellar atrophy (CA) is a frequent neuroimaging finding in paediatric neurology, usually associated with cerebellar ataxia. The list of genes involved in hereditary forms of CA is continuously growing and reveals its genetic complexity. We investigated ten cases with early-onset cerebellar involvement with and without ataxia by exome sequencing or by a targeted panel with 363 genes involved in ataxia or spastic paraplegia. Novel variants were investigated by in silico or experimental approaches. Seven probands carry causative variants in well-known genes associated with CA or cerebellar hypoplasia: SETX, CACNA1G, CACNA1A, CLN6, CPLANE1, and TBCD. The remaining three cases deserve special attention; they harbour variants in MAST1, PI4KA and CLK2 genes. MAST1 is responsible for an ultrarare condition characterised by global developmental delay and cognitive decline; our index case added ataxia to the list of concomitant associated symptoms. PIK4A is mainly related to hypomyelinating leukodystrophy; our proband presented with pure spastic paraplegia and normal intellectual capacity. Finally, in a patient who suffers from mild ataxia with oculomotor apraxia, the de novo novel CLK2 c.1120T>C variant was found. The protein expression of the mutated protein was reduced, which may indicate instability that would affect its kinase activity.

30 November 2021 in Frontiers in Neurology
Verified
Journal Article
Open access
AHAna Victoria Marco Hernández
Ana Victoria Marco Hernández
MVMiguel Tomás Vila
Miguel Tomás Vila
ALAlfonso Caro Llopis
Alfonso Caro Llopis
SMSandra Monfort
Sandra Monfort
FMFrancisco Martinez
Francisco Martinez
Dominant pathogenic variations in the SCN1A gene are associated with several neuro developmental disorders with or without epilepsy, including Dravet syndrome (DS). Conversely, there are few published cases with homozygous or compound heterozygous variations in the SCN1A gene. Here, we describe two siblings from a consanguineous pedigree with epilepsy phenotype compatible with genetic epilepsy with febrile seizures plus (GEFS+) associated with the homozygous likely pathogenic variant (NM_001165963.1): c.4513A > C (p.Lys1505Gln). Clinical and genetic data were compared to those of other 10 previously published patients with epilepsy and variants in compound heterozygosity or homozygosity in the SCN1A gene. Most patients (11/12) had missense variants. Patients in whom the variants were located at the cytoplasmic or the extracellular domains frequently presented a less severe phenotype than those in whom they are located at the pore-forming domains. Five of the patients (41.7%) meet clinical criteria for Dravet syndrome (DS), one of them associated acute encephalopathy. Other five patients (41.7%) had a phenotype of epilepsy with febrile seizures plus familial origin, while the two remaining (17%) presented focal epileptic seizures. SCN1A-related epilepsies present in most cases an autosomal dominant inheritance; however, there is growing evidence that some genetic variants only manifest clinical symptoms when they are present in both alleles, following an autosomal recessive inheritance.